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The role of surgery in clinical stage T3 prostate cancer (cT3 PCa) is still subject to debate. We reviewed the records of 139
consecutive patients who underwent a radical prostatectomy (RP) for cT3 PCa with a mean follow-up of 8 years. All data
related to surgical and perioperative complications were collected. Continence and erectile function were assessed at 12 months
postoperatively and long-term oncologic outcomes were analyzed. Rectal injury and injury of the obturator nerve occurred both
in 0.7% of cases. No serious in-hospital complications were noted and no reintervention was needed. Lymphatic leakage was noted
in 2.2% of patients and 1.4% experienced prolonged drainage of urine. In 7.2%, wound-related problems occurred. Anastomotic
stricture occurred in 2.9%. These complication rates were not diﬀerent compared to surgical series of RP in localized PCa. At 12
months, complete continence was 87.8% and erectile function had fully recovered in 6% and 10% of patients who underwent a
non-nerve sparing or unilateral nerve-sparing procedure, respectively. 10-year estimated biochemical PFS, clinical PFS, CSS and
OS were 51.8%, 85.6%, 94.6% and 85.9%, respectively. In cT3 PCa, RP is technically feasible with morbidity comparable to RP in
clinically localized PCa. Long-term oncologic control was excellent.
1.Introduction
Locally advanced prostate cancer (PCa) is deﬁned as cancer
thathasextendedclinicallybeyondtheprostaticcapsulewith
invasion of the pericapsular tissue, the sphincter muscle,
bladder neck, or seminal vesicles, but without lymph node
involvement or distant metastases [1]. Locally advanced PCa
is referred to as clinical stage T3-4 N0 M0 disease. T-staging
is mainly based on the ﬁndings of digital rectal examination,
while transrectal ultrasound, PSA level, PSA density, and the
extent of cancer in prostate biopsies may provide additional
information[2].Inarecentpopulation-basedSwedishstudy,
18.6% of prostate cancers presented as locally advanced,
nonmetastatic PCa [3]. In another recent paper, based upon
data from the SEER (Surveillance, Epidemiology, and End
Results) database, between 11.6% and 15.3% of the patients
presentedwithcT3N0M0PCa,while8%to10.9%presented
with T4 and/or N1 and/or M1 PCa [4]. These data from
Europe and the US provide an estimation of the incidence
of cT3-4 PCa, which is thought to be between 15 and
25%.
The optimal treatment of cT3 PCa has been subject to
intense debate during recent years. According to the guide-
lines of the European Association of Urology (EAU), watch-
ful waiting, radiation therapy (RT), Radical prostatectomy
(RP),hormonaltherapy(HT),andvariouscombinationsare
valuableoptionstoconsider,dependingonthegeneralhealth
status of the patient and the local extent of the tumour [5].
Many experts consider an RP for cT3 PCa a valid trea-
tment option with excellent oncological outcome, but it is
felt to be a burdensome procedure even for a skilled surgeon
and feasibility has been questioned in the past.
In order to better deﬁne the place of surgery in cT3 PCa,
we have conducted a retrospective study in 139 patients who
underwentanRPforcT3PCa.Thepatientﬁleswerecritically
reviewed and all data related to surgical and peri-operative
complicationswerecarefullycollected.Alldatawerecompar-
ed to major contemporary series of RP in clinically localised
disease. Additionally, functional results with respect to erec-
tile function and continence were collected at 12 months
postoperatively and long-term oncologic outcomes were as-
sessed.2 Advances in Urology
2.MaterialandMethods
From January 1997 to December 2003 we performed an
RP with bilateral pelvic lymphadenectomy in 139 patients
with cT3 PCa. Ultrasound guided prostate biopsies showed a
median Gleason score of 7 (range 2–10). Prostate biopsy was
performed in accordance with the random systematic octant
biopsy technique: lateral systematic sextant biopsies with
additional bilateral transition zone biopsies [6]. Additional
biopsies were directed to the sites of abnormal digital rectal
examination and abnormal transrectal ultrasound ﬁndings.
Local staging was routinely performed by digital rectal ex-
amination and transrectal ultrasound. In 16 patients, en-
dorectal coil magnetic resonance imaging was included to
reﬁne the local staging. Lymph node status was examined
through a contrast-enhanced CT scan of the pelvis (n = 122)
or an MRI scan (n = 4). Distant metastases were excluded
by a bone scan (n = 123). In patients with PSA <10ng/mL
and a biopsy Gleason score <7, N and M staging was not
performed, as the risk for nodal involvement in this group
is estimated to be very low (≤4%) [7]. 125 patients (89.9%)
were staged cT3a N0 M0 and 14 (10.1%) cT3b N0 M0
(Table 1).
As described earlier, our surgical technique focuses on
clean apical dissection, neurovascular bundle resection at
least at the tumour bearing site, complete resection of the
seminal vesicles, and in some cases resection of the bladder
neck [8]. In 129 patients (92.8%), a bilateral non-nerve-
sparing RP was performed. In only 10 patients (7.2%), a uni-
lateral nerve-sparing procedure was possible. In 10 patients
(7.2%) a lymphadenectomy was not performed because of
previous pelvic surgery or a low PSA level (<10ng/mL)
associated with a biopsy Gleason score <7.
In the peri-operative period, low molecular weight
heparin and compression stockings were administered as
thromboembolic prophylaxis. Postoperative pain was man-
aged for 2 days by epidural patient-controlled anaesthesia.
Oral ingestion and early mobilisation was encouraged from
the ﬁrst postoperative day. Patients were discharged after
removal of all suction drains (as soon as drainage was fewer
than 15mL per 24h), as soon as they were on a normal
diet and were fully ambulatory and pain or discomfort was
manageable by oral analgesia. The urethral catheter was left
in situ at discharge and was removed during a one-night
hospital stay at a mean of 12 days postoperatively. Since our
group has shown that pelvic ﬂoor muscle exercises shorten
the duration of incontinence and improve continence rates
after an RP, physiotherapy was started at catheter removal
[9].Patientswhoremainedincontinentat1yearwereoﬀered
the possibility of an artiﬁcial urethral sphincter implant.
At 6 to 8 weeks postoperatively, patients were reassessed
for the ﬁrst time and serum PSA was measured. For the ﬁrst
postoperative year, patients were seen at 3-month intervals.
For the second and third years, patients were reevaluated
every 4 months and 6 months thereafter.
Patients who underwent a unilateral nerve-sparing pro-
cedure were oﬀered treatment with 5-phosphodiesterase-in-
hibitors, or intracavernous prostaglandin E2 injections if the
obtained eﬀect was insuﬃcient. Patients who underwent a
Table 1: Patient characteristics.
Number of patients 139
Age (years), mean (±SD) 61,8 (±7,0)
cT3a 89,9% (n = 125)
cT3b 10,1% (n = 14)
Biopsy Gleason score, median (range) 7 (2–10)
PSA (ng/mL), mean (range) 13,73 (3,1–97,0)
Previous surgery 14,4% (n = 20)
Neo-Adjuvant Androgen Deprivation Therapy 8,6% (n = 12)
Non-nerve-sparing procedure 92,8% (n = 129)
Unilateral nerve sparing procedure 7,2% (n = 10)
Lymphadenectomy not performed 7,2% (n = 10)
Hospital stay (days), median (range) 12 (5–27)
pT2 31,1% (n = 42)
pT3a 51,1% (n = 69)
pT3b 16,3% (n = 22)
pT4 1,5% (n = 2)
PSA persistence 10,1% (n = 14)
Pathological Gleason score, median (range) 7 (4–9)
Pathological node positive 10,1% (n = 14)
Surgical margin positive 13,7% (n = 19)
Adj radiation therapy within 1 year 7,2% (n = 10)
Adj endocrine therapy within 1 year 13,7% (n = 19)
non-nerve-sparingoperationwereoﬀeredtreatmentwithin-
tracavernous injections.
Further treatment strategy was based upon ﬁnal histo-
pathology and PSA evolution. In case of positive surgical
margins, patients were randomised according to the EORTC
22911 protocol to receive adjuvant pelvic irradiation or
not [10]. In case of positive lymph nodes, early endocrine
treatment was initiated. Invasion of the seminal vesicles with
negative surgical margins was not an indication for early
adjuvant therapy. A slowly rising PSA (PSA doubling time
>12 months) in the absence of positive surgical margins
or positive lymph nodes was interpreted as local relapse
for which the patient was treated with pelvic irradiation
(60Gy). A PSA persistence in the presence of negative
surgical margins and any steep rising PSA (PSA doubling
time ≤12 months) after a period of undetectable nadir were
both considered a sign of occult metastasis. Therefore, these
patients were treated with endocrine treatment.
3. Results
Patient characteristics are described in Table 1.M e a na g e
of the patients was 61.8 years (SD 7.0). Mean PSA was
13.7ng/mL (range <0.02–97.0). Mean follow-up of the study
was 98 months (range 7–162). Twenty patients (14.4%)
had undergone previous pelvic surgery: inguinal hernia
repair in 19 and surgery for pelvic fracture in one. Twelve
patients (8.6%) had received neoadjuvant HT prior to
surgery. No patient had undergone pelvic radiotherapy. In
our population of 139 patients, mean operative time was 105
minutes (range 50–180) with a mean blood loss of 558mLAdvances in Urology 3
(range 100–2100). The urethral catheter was removed at day
12 (range 10–15). Mean admission time was 12 days (range
5–27).
3.1. Complications and Functional Results. Preoperatively, no
ureteral or vascular injury occurred. Operative complica-
tions included one sectioning of the obturator nerve (0.7%)
and one rectal laceration (0.7%). Treatment consisted of
microsurgical repair of the obturator nerve and primary
closure of the rectal laceration in a double layer. Long-term
evolution was uneventful in both cases. No peri-operative
mortality was noted.
In the peri-operative period no ureteral obstruction or
urinary retention occurred. In 10 patients (7.2%) healing
of the abdominal wound was delayed: 6 wound infections
(4.3%) and 4 partial wound dehiscences (2.9%) occurred.
Prolonged drainage in the suction drains was noted in 5
patients. Lymphatic leakage was present in 3 cases (2.2%).
Twopatients(1.4%)hadaurinaryleakagefor36hourswhich
resolved spontaneously with permanent suction. Prolonged
drainage did not show to be prognostically relevant since all
5 patients obtained total continence at 12 months. All above
mentioned patients were discharged without reintervention.
When lower urinary tract symptoms were present, a
uroﬂowmetry was performed: within 12 months, 4 patients
(2.9%) were diagnosed with an anastomotic stricture. One
patient complained of a painful orgasm. Urethroscopy
visualised a surgical clip at the level of the anastomosis. After
removal of the clip, the dysorgasmia disappeared.
At 12 months, 98 patients were completely continent
(70.5%) and 24 patients mentioned an occasional loss of a
drip (17.3%). Incontinence for which protective pads were
needed was only seen in 17 patients (12.2%). Of these 17
patients, one had already been treated for overactive bladder.
Only6ofthese17patientsneededmorethanonepadperday
(4.3%). And only 2 of them complained of continuous and
uncontrollable incontinence: an artiﬁcial urinary sphincter
was therefore implanted (1.4%). Postoperative potency was
evaluated at 12 months. 129 patients were treated by a non-
nerve-sparing RP. 83.6% mentioned absence of erections;
10.4% experienced some tumescence, but not suﬃcient for
vaginal intercourse, and 6% patients had erections, suﬃcient
for successful vaginal intercourse. Mean age of these last
patients was only 54.5 years (range 49.8 to 62.2 years). In the
10 patients who were treated with a unilateral nerve sparing
procedure, erections did not recur in 40% and did recur
partiallythoughinsuﬃcientlyforvaginalintercoursein50%;
10% regained full erectile function.
Table 2 [11–16] compares the operative characteristics,
peri-operative complications and mortality, late postoper-
ative complications, and functional results of our present
series of RP in locally advanced PCa with major series of
RP in clinically localized PCa [11–15] and 1 series of RP
in locally advanced PCa (Lerner) [16]. Mean blood loss
ranged from 600 to 872mL in the organ-conﬁned series,
which compares favourably with our series (558mL) and
the series by Lerner (945mL). Rectal, ureteral, and obturator
nerve injury occurred in 0.3–4.9%, 0.1–0.8%, and 0.3–1.6%,
respectively, in the organ-conﬁned PCa series. These results
again compare favourably with the present series (0.7%,
0%, and 0.7%, resp.). In the series by Lerner, only rectal
injury was mentioned (1.8%), while ureteral and obturator
nerve injuries were not. Wound problems ranged from 0.9 to
13.8%, while reinterventions were rare at 0.5–1.7%. Again,
this was not diﬀerent in our series (7.2% and 0%, resp.) and
the series by Lerner (2.7% and NA, resp.). Nonsurgical com-
plications varied, but were infrequent, both in the literature
reviewed as in the present analysis. Long-term complications
(measured at 12 months) were mainly anastomotic strictures
(range 0.7–13.8%) and incontinence, requiring pad use (12–
20%).Thesewerecomparabletoourseries(2.9%and12.2%,
resp.) and the Lerner series (9.2% and 22.1%, resp.).
3.2. Oncologic Outcomes. At ﬁnal histopathology, in 19 pa-
tients, positive surgical margins were found (13.7%). Of
these specimens with positive surgical margins, 2 tumours
were organ conﬁned (pT2), 12 showed extraprostatic exten-
sion(pT3a),4wereinvadingtheseminalvesicles(pT3b),and
one had invaded the bladder neck (pT4). Table 3 provides
an overview on the percentage of positive section margins
according to the pathologic stage. In 14 patients, positive
lymph nodes were found (10.1%). 13 were staged as clinical
N0 by contrast-enhanced CT scan (n = 12) or MRI scan
(n = 1). In one patient, preoperative lymph node staging
was not performed because of PSA <10ng/mL and biopsy
Gleason score <7.
Postoperative evaluation included history, physical ex-
amination, and serum PSA measurement. PSA persistence
(>0.02ng/mL) at ﬁrst follow-up was found in 14 patients
(10.1%). These cases were considered surgical failures. In 10
of these 14 patients (71.4%), ﬁnal histopathology revealed
positive surgical margins or positive lymph nodes. Within
one year, 10 patients (7.2%) underwent RT of the pelvis and
19 patients (13.7%) were started on endocrine treatment
because of positive surgical margins, PSA persistence, or
rising PSA (Table 1). At a mean follow-up of 98 months
(median98,range7–162),35.5%ofthepatientshadreceived
adjuvant or salvage RT and 38.8% of the patients had re-
ceived adjuvant or salvage HT.
Thelong-termoncologicoutcomeswereassessedbyKap-
lan-Meier survival estimates. The 10-year estimated bio-
chemical progression-free survival, clinical progression-free
survival, cancer speciﬁc survival, and overall survival rates
were 51.8%, 85.6%, 94.6%, and 85.9%, respectively, (Figures
1(a)–1(d)).
4. Discussion
TreatmentoptionsforlocallyadvancedPCavaryandthejury
is still out regarding the optimal treatment [17]. Watchful
waiting, RT, HT, surgery, and combinations have been pro-
posed.
IncT3PCa,Thompsonreporteda60to70%5-yearover-
all survival with watchful waiting [18]. Similarly, Johansson
et al. mention a 15-year progression-free survival rate of
46.6% and a disease-speciﬁc survival rate of 56.5% [19].4 Advances in Urology
Table 2: Complication rates after open radical retropubic prostatectomy.
Joniau Dillioglugil
et al. [11]
Hisasue
et al. [12]
Gaylis et al.
[13]
Maﬀezzini
et al. [14]
Lepor et al.
[15]
Lerner et al.
[16]
Number of patients 139 472 123 116 300 1000 812
cT1 % (pT1 %) 0 20.3 44.7 43 (0) 78.5 0
cT2 % (pT2 %) 0 72.7 55.3 57 (66.4) 21.3 0
cT3 % (pT3 %) 100 6.9 0 0 (29.9) 0.2 100
Mean age (years) 62.0 63 66 66.6 65.5 60.3
Mean operation time (min) 105 155
Mean blood loss (mL) 558 872 600 945
Mortality % 0 0 0 0.4
Rectal injury % 0.7 0.6 4.9 0.9 0.3 0.5 1.8
Ureteral injury % 0 0.2 0.8 0.3 0.1
Iliac vessel injury % 0 1.1
Obturator nerve injury % 0.7 0.2 1.6 0.3
Angor/myocardial infarction % 0.7 1.7 0.6 0.4
Other cardiac complications % 0 10.6 0.8 0.2
Pulmonary complications % 0 3.8 0.1
Deep venous thrombosis/pulmonary
embolism % 0 2.3 0.8 3.4 0.3 0.3 4
Gastrointestinal complications % 0 5.1 0.8 0.6
Neurological complications % 1.4 1.5 0.2
Other infectious complications % 0 4.7 0.8 0
Prolonged drainage (urine, lymph, blood) % 3.6 2.8 8.9 2 0.7 0.8
Acute retention % 0 0.6 2
Reintervention % 0 1.7 0.5
Woundproblem % 7.2 3.0 13.8 0.9 1 0.8 2.7
Anastomotic stricture at 12 months % 2.9 13.8 0.7 1 9.2
Not dry (in need of pads) at 12 months % 12.2 12.7 20 12 22.1
Table 3:Comparisonbetweenpositivesurgicalmarginsandpatho-
logic staging after radical retropubic prostatectomy.
Positive surgical margins
All patients 13.7%
pT2 4.8%
pT3a 17.4%
pT3b 18.2%
pT4 50%
cT3 PCa is therefore regarded as a signiﬁcant tumour with a
considerable associated mortality, especially in patients with
a long life expectancy. Thus, watchful waiting is only allowed
in a strict minority of selected patients with a poor general
health status [18, 19].
Until the early eighties, radiotherapy was the treatment
of choice for localized and locally advanced PCa. With ra-
diotherapy as monotherapy, 10-year disease-free survival
rates of 19–44% and overall survival rates of 21–54% have
been reported [20–23]. At 25-year follow-up, radiotherapy
as monotherapy only added a neglectable gain in survival.
When patients did not die of intercurrent disease, they were
highly likely to develop recurrence and to die of PCa [20].
Inanattempttoimprovedisease-freesurvivalandoverall
survival, the combination of RT and HT was evaluated.
Laverdiereetal.hadindeedshownasigniﬁcantimprovement
in oncological outcome with adjuvant HT [24]. These ﬁnd-
ings were corroborated in randomised trials of the European
Organisation for Research on Treatment of Cancer (EORTC)
and the Radiation Therapy Oncology Group (RTOG) [25,
26]. The EORTC trial 22863 turned out to be a milestone
study. Disease-speciﬁc survival and overall survival rates at
5 years improved from 79% to 94% and from 62% to 78%,
respectively, in favour of combined RT and HT. Neoadjuvant
HT was evaluated in the RTOG 86-10 trial. A signiﬁcant
decrease in local and distant progression and a signiﬁcant
increase in disease-free survival and disease-speciﬁc survival
were noted at a mean follow-up of 8 years. However, overall
survival did not increase signiﬁcantly [27].
By many, the combination of external-beam RT and ad-
juvant HT is since considered a standard therapeutic option
in patients with cT3 PCa.
Literature on the value of RP as an option for cure in
cT3 PCa is limited. However, clinical evidence showing 5-
year disease-speciﬁc survival rates ranging between 85% and
100% is available [28–31]. Additionally, RP can prevent lo-
cal tumour-associated complications and provide a clearAdvances in Urology 5
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Figure 1: Kaplan-Meier plots for the oncologic outcomes of surgery for cT3a-b PCa. (a) Biochemical progression-free survival. (b) Clinical
progression-free survival. (c) Cancer-speciﬁc survival. (d) Overall survival.
Table 4: The percentage of overstaging and understaging in clinical
locally advanced T3 prostate cancer.
Authors pT2 pT4/N+
Van Poppel et al. [28] 13% 8%/11%
Van den Ouden et al. [29] 15% 3.4%/15.6%
Lerner et al. [16] 17% —/33%
Morgan et al. [32] 22% 42% (stage D1)
Ward et al. [33] 27% —/27%
deﬁnition of failure after therapy compared to the more
vaguely deﬁned failure parameters after RT. Furthermore,
overstaging of cT3 PCa ranges from 13 to 27% (pT2) (Table
4)[ 16, 28, 29, 32–34]. In pT2, RP has a very high chance of
cure and long-term outcome after RP is very good [34].
Some locally advanced PCa will not be cured by surgery
alone, and therefore, combinations with hormone therapy
or radiotherapy have been investigated. Neoadjuvant HT
did not improve biochemical or clinical progression, nor
survival rates in RP [35–37]. Adjuvant HT after RP has
shown to be beneﬁcial, especially in poor prognosis disease
[16]. Early adjuvant RT has also shown a lower risk of local
recurrence, a longer time to progression, and an improved
cancer-speciﬁc and overall survival [10, 38]. This eﬀect
was also more pronounced in high-risk patients: EORTC
trial 22911 showed a clear improvement of progression-free
survival and local control in patients with positive surgical
margins or pT3 prostate cancer when RP was combined with
RT [10]. Recently, long-term follow-up of cT3 PCa treated
primarily with a prostatectomy has been published. Majority
of patients underwent adjuvant RT and/or HT. 5-, 10-, and
15-year disease-free survival and disease-speciﬁc survival
rates were 85%, 73%, and 67% and 95%, 90%, and 79%,
respectively [33].
The general impression is that complications such as rec-
tal injury, haemorrhage, deep venous thrombosis, pulmona-
ry embolism, urinary ﬁstula, ureteral obstruction, stress in-
continence, impotence, anastomotic stricture, and peri-
operative death are more common in the cT3 patient
group. Our review of literature shows that the mortality
risk associated with RP is merely a theoretical risk. Other6 Advances in Urology
surgery-related complications such as rectal injury, ureteral
obstruction, and injury to the iliac vessels or obturator
nerves are encountered rarely and do not account for a
signiﬁcant amount of morbidity. At an incidence between
0.6% and 7.3%, all of these per-operative complications
could be resolved during the same operation. Long-term
consequences such as anastomotic strictures occur in 0.7%
to 13.8% of patients. One single dilatation has a success rate
of up to 75% [12, 14]. Another late problem is incontinence.
In12%to22.1%ofpatients,atleastoneprotectivepadisstill
needed at 12 months [11–16, 33].
In Table 2, we compare the complication rates and
functional results of our series of 139 cT3 PCa patients
with some major contemporary RP series in organ-conﬁned
and 1 series of RP in locally advanced PCa. Postoperative
complications are grouped according to organ system. With
absent mortality, a peri-operative complication rate of 1.4%,
andpostoperativecomplicationrateof12.9%,ourcT3popu-
lation is exposed to an equal risk of complications compared
to patients who undergo an RP for cT1 or cT2 tumours. At
the same time, our results compare favourably with those
mentioned by Lerner in RP for locally advanced PCa. The
only paper which has so far directly compared surgical com-
plications in locally advanced PCa versus localized disease in
a single institution is from Gontero et al. The two groups
did not diﬀer signiﬁcantly in surgical morbidity except for
blood transfusion, operative time, and lymphoceles, which
showed a higher rate in patients with advanced disease [39].
We corroborate these results in our present analysis.
Furthermore, in our series, functional results at 12
months show total continence (no pad necessary) in 87.8%
and socially acceptable continence (max. 1 precautionary
pad) in 94.2%, which is well within acceptable ranges. Final-
ly, anastomotic stricture was encountered at a rather low
rate of 2.9%. Expectedly, potency rates were poor in non-
nerve-sparing RP (6% full recovery at 1 year and 10% partial
recovery), while those rates were better in unilateral nerve-
sparing RP (10% full recovery and 50% partial recovery).
As complete recovery of erectile function can take up to
36 months, further improvement of these results may be
expected [40]. Furthermore, modern imaging (Magnetic
Resonance Imaging (MRI), diﬀusion-weighted MRI) allows
more accurate preoperative assessment of tumour invasion
in the neurovascular bundle, further increasing the indica-
tions for a nerve-sparing approach [41].
Surgical margins after RP are of great importance in pro-
gression and oncological outcome [42–46]. Margin positive
status varies between 29% and 60.5% in the corresponding
articles. The lowest incidence of positive margins was 29%
and was found in a population of predominantly organ-
conﬁned PCa (73.7% pT2) [42]. In our series of cT3 PCa,
31.1% were pT2. Positive surgical margins were found in
only13.7%,whichisthelowestrateinliteraturetoourknow-
ledge. It is clear, though, that surgery for locally advanced
PCahadaconsiderablelearningcurve.Atourinstitution,the
learning curve translated into a dramatic decrease in positive
margin rates from 66.7% in the period 1987–1994 to 43.3%
in the period 1995–1999 to 10.0% in the period 2000–2004
[7].
Our present analysis is not devoid of limitations. First,
this is a retrospective analysis of complications and func-
tional results, using data extracted from patient ﬁles. Inher-
ent biases are to be expected, as sometimes more discrete
complications can be missed. Second, preoperative data on
the functional status of the patient were not collected, limit-
ing the interpretation of the results. Third, the complications
and functional results were compared to data extracted from
the literature. Indeed, a more solid approach would be to
prospectively compare data on RP in cT3a-b PCa with data
on RP in localized disease from the same institution. Never-
theless, we believe that our analysis has its value in outlining
theincidenceofcomplicationsandthefunctionalresultsthat
can be expected after RP for locally advanced PCa. It has
to be stressed that data on this subject are extremely scarce.
Finally, a signiﬁcant number of patients received adjuvant or
salvage RT and/or HT treatment following surgery, limiting
theinterpretationoftheresultsregardingthevalueofsurgery
in locally advanced PCa. Accepting this limitation, oncologic
control with RP as a ﬁrst step in the treatment of locally
advanced PCa is excellent.
5. Conclusion
Our experience with 139 patients conﬁrms the surgical fea-
sibility of RP for cT3 PCa, showing complication rates com-
parable with RP in organ-conﬁned PCa and showing a
very low incidence of positive surgical margins and asso-
ciated failure of surgery. Improvement can be expected by
further deﬁning the patient population most suitable for
surgery and by further optimising adjuvant treatments such
as RT and HT. Continence rates were also comparable with
those achieved after RP for localized PCa. A nerve-sparing
approach was only considered possible in a limited number
of patients. It has to be expected, though, that modern imag-
ing will further increase the indications for nerve-sparing
surgery in locally advanced PCa.
Prospectiverandomizedclinicaltrialsareneededtocom-
pare oncological outcome, treatment-related complications,
and quality of life in the diﬀerent treatment options for cT3
PCa.
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